Finepoint Capital LP Purchases Shares of 660,000 Xencor, Inc. (NASDAQ:XNCR)

Finepoint Capital LP acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 660,000 shares of the biopharmaceutical company’s stock, valued at approximately $15,167,000. Xencor accounts for about 0.9% of Finepoint Capital LP’s holdings, making the stock its 11th largest position. Finepoint Capital LP owned approximately 0.94% of Xencor at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after acquiring an additional 418,040 shares during the period. Loomis Sayles & Co. L P lifted its holdings in Xencor by 21.3% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company’s stock worth $25,102,000 after purchasing an additional 192,080 shares during the period. Geode Capital Management LLC grew its position in Xencor by 12.3% in the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company’s stock valued at $37,578,000 after buying an additional 179,526 shares in the last quarter. Norges Bank acquired a new position in Xencor during the 4th quarter valued at about $3,397,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Xencor during the 4th quarter worth about $2,329,000.

Analyst Ratings Changes

A number of research analysts recently commented on XNCR shares. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Down 2.6 %

Xencor stock opened at $8.69 on Friday. The firm’s 50 day moving average price is $14.51 and its two-hundred day moving average price is $19.69. The firm has a market cap of $612.31 million, a PE ratio of -2.72 and a beta of 0.90. Xencor, Inc. has a twelve month low of $8.45 and a twelve month high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. On average, research analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.